Revolution Medicines (RVMDW) Amortization of Deferred Charges (2021 - 2026)

Revolution Medicines' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges rose 24.59% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $8.3 million (up 66.9% YoY), while the FY2025 annual figure was $7.9 million, up 88.47% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $2.2 million, down from $2.4 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $2.4 million in Q4 2025, with the low at $283000.0 in Q2 2023.
• The 5-year median for Amortization of Deferred Charges is $1.2 million (2022), against an average of $1.3 million.
• The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges slumped 75.09% in 2023, then jumped 213.78% in 2024.
• Revolution Medicines' Amortization of Deferred Charges stood at $1.2 million in 2022, then climbed by 5.25% to $1.2 million in 2023, then gained by 11.33% to $1.4 million in 2024, then jumped by 70.83% to $2.4 million in 2025, then slipped by 7.48% to $2.2 million in 2026.
• Business Quant data shows RVMDW's Amortization of Deferred Charges at $2.2 million in Q1 2026, $2.4 million in Q4 2025, and $2.0 million in Q3 2025.